Abstract:Multiple sclerosis [MS] is a progressive autoimmune condition that primarily affects young people and is characterized by demyelination and neurodegeneration of the central nervous system [CNS]. This in-depth review explores the complex involvement of oligodendrocytes, the primary myelin- producing cells in the CNS, in the pathophysiology of MS. It discusses the biochemical processes and signalling pathways required for oligodendrocytes to function and remain alive, as well as how they might fail and cause demyelination to occur. We investigate developing therapeutic options that target remyelination, a fundamental component of MS treatment. Remyelination approaches promote the survival and differentiation of oligodendrocyte precursor cells [OPCs], restoring myelin sheaths. This improves nerve fibre function and may prevent MS from worsening. We examine crucial parameters influencing remyelination success, such as OPC density, ageing, and signalling pathway regulation [e.g., Retinoid X receptor, LINGO-1, Notch]. The review also examines existing neuroprotective and antiinflammatory medications being studied to see if they can assist oligodendrocytes in surviving and reducing the severity of MS symptoms. The review focuses on medicines that target the myelin metabolism in oligodendrocytes. Altering oligodendrocyte metabolism has been linked to reversing demyelination and improving MS patient outcomes through various mechanisms. We also explore potential breakthroughs, including innovative antisense technologies, deep brain stimulation, and the impact of gut health and exercise on MS development. The article discusses the possibility of personalized medicine in MS therapy, emphasizing the importance of specific medicines based on individual molecular profiles. The study emphasizes the need for reliable biomarkers and improved imaging tools for monitoring disease progression and therapy response. Finally, this review focuses on the importance of oligodendrocytes in MS and the potential for remyelination therapy. It also underlines the importance of continued research to develop more effective treatment regimens, taking into account the complexities of MS pathology and the different factors that influence disease progression and treatment.

CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases

Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology

Inhibition of CXCR2 enhances CNS remyelination via modulating PDE10A/cAMP signaling pathway

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

Wnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

The role of CXCL1/CXCR2 axis in neurological diseases

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis

Remyelination in the CNS: from biology to therapy

Demyelination-remyelination in the Central Nervous System: Ligand-dependent Participation of the Notch Signaling Pathway

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1

Connexin 43 Deletion in Astrocytes Promotes CNS Remyelination by Modulating Local Inflammation

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

CCL21/CCR7 Axis Regulates Demyelination and Vascular Cognitive Impairment in a Mouse Model for Chronic Cerebral Hypoperfusion

Demyelinating processes in aging and stroke in the central nervous system and the prospect of treatment strategy

Promoting Remyelination in Central Nervous System Diseases: Potentials and Prospects of Natural Products and Herbal Medicine

An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination